Quick summary
Palmitoyl Tripeptide-5 (SYN-COLL) is a lipopeptide that mimics thrombospondin-1 to activate TGF-beta and stimulate collagen synthesis. It provides dual action by both promoting new collagen I and III production and inhibiting MMPs that degrade existing collagen.
Overview
Palmitoyl Tripeptide-5 is a lipopeptide composed of the tripeptide Lys-Val-Lys (KVK) conjugated to palmitic acid, marketed under the trade name SYN-COLL. It was developed as a synthetic mimic of thrombospondin-1 (TSP-1) to activate the TGF-β pathway and stimulate endogenous collagen synthesis. It is a widely adopted anti-aging active in premium serums and moisturizers, valued for its dual collagen-synthesis and MMP-inhibition activity.
Mechanism of action
Palmitoyl Tripeptide-5 mimics the TSP-1 sequence that activates latent transforming growth factor-beta (TGF-β). By binding to the latency-associated peptide region of inactive TGF-β, the tripeptide induces release of the active growth factor, which then signals dermal fibroblasts via Smad2/3 phosphorylation to upregulate type I and III collagen synthesis. Simultaneously, Palmitoyl Tripeptide-5 inhibits matrix metalloproteinases (MMP-1, MMP-2, MMP-9) that degrade existing collagen, providing a dual protective and regenerative action. The palmitoyl lipid chain enhances penetration through the stratum corneum and increases residence time in the dermis by anchoring the peptide to membrane phospholipids.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| collagen-stimulating anti-aging application | topical | 1–4 % | once or twice daily | Effective at 1–4% in finished formulations. Stable at pH 4.5–7.5. Compatible with most actives including retinol and vitamin C. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Manufacturer-sponsored clinical studies (Lipotec / Lubrizol) report measurable reductions in wrinkle depth and improvements in skin firmness after 28–56 days of twice-daily application versus placebo. In vitro fibroblast assays demonstrate statistically significant increases in collagen I and III mRNA expression. A 2025 PMC review of anti-aging peptides cites Palmitoyl Tripeptide-5 among well-characterized matrikine-class cosmetic actives with consistent in vitro evidence. Independent peer-reviewed clinical trials remain limited as of 2026.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Palmitoyl Tripeptide-5 for synergistic effects.
Legal status
Cosmetic ingredient with unrestricted OTC status globally. Sold as a cosmetic active; not classified as a drug by FDA, EMA, or equivalent bodies. No known regulatory advisories.
Sourcing & access
Research compound
Palmitoyl Tripeptide-5 is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Palmitoyl Tripeptide-5, marketed as SYN-COLL, is a lipopeptide composed of the KVK tripeptide conjugated to palmitic acid. It was developed as a synthetic mimic of thrombospondin-1 to stimulate endogenous collagen synthesis for anti-aging skincare.
It mimics the TSP-1 sequence that activates latent TGF-beta, triggering fibroblast signaling via Smad2/3 phosphorylation to upregulate type I and III collagen synthesis. Simultaneously, it inhibits MMP-1, MMP-2, and MMP-9 that degrade existing collagen, providing dual protective and regenerative action.
It is generally well tolerated as an unrestricted OTC cosmetic ingredient globally. The only rarely reported side effect is mild transient redness at high concentrations. It is stable at pH 4.5-7.5 and compatible with most actives including retinol and vitamin C.
Clinical studies report measurable reductions in wrinkle depth and improvements in skin firmness after 28 to 56 days of twice-daily application. It is formulated at 1-4% concentration in finished products.
Research references
- Topical palmitoyl pentapeptide provides improvement in photoaged human facial skinPubMed
- Supramolecular collagen nanoparticles for anti-wrinkle, skin whitening, and moisturizing effects via synergistic action of palmitoyl peptide and niacinamidePubMed
- Peptides stimulating synthesis of extracellular matrix used in anti-ageing cosmetics: Are they clinically tested? Assessment based on the analysis of clinical trialsPubMed